• Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

  • Jun 16 2022
  • Length: 2 mins
  • Podcast

Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

Listen for free

View show details

  • Summary

  • EMPRISE is a 5-year monitoring program that uses Medicare and two commercial claims in the United States to assess the efficacy and safety of empagliflozin (EMPA). A total of 190,226 type 2 diabetes patients aged 18 years or older who started EMPA or a dipeptidyl peptidase-4 inhibitor (DPP-4i) and were followed for heart failure hospitalization in primary or any discharge position a composite of MI and stroke, and all-cause mortality (ACM). Safety outcomes were lower-limb amputations (LLA), non-vertebral fractures, diabetic ketoacidosis (DKA), acute kidney injury (AKI), renal and bladder cancers.

    EMPA was linked to a lower risk of hospitalization for heart failure, a similar risk of MI or stroke, and a lower risk of all-cause mortality when compared to DPP4i. EMPA was associated with lower risk of acute kidney injury, higher risk of diabetic ketoacidosis, and a similar risk of lower-limb amputations, fractures, and renal and bladder cancer.

    In conclusion, these findings back up EMPA's cardiovascular effectiveness in normal treatment, with a safety profile that matches recorded data.
    Show More Show Less
Show More Show Less

What listeners say about Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.